相关实验视频

Updated: Mar 15, 2026

In Vitro Synthesis of Modified mRNA for Induction of Protein Expression in Human Cells

In Vitro Synthesis of Modified mRNA for Induction of Protein Expression in Human Cells

Published on: November 13, 2014

CJ-1:一个优化的mRNA平台,具有增强的蛋白质表达和最小的免疫性,用于治疗应用

Seyoung Kim^1,2, Min Ju Jo^1,2, Min Seon Jeong^1,3

¹Nucleic Acid Therapeutics Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju, Republic of Korea.

|March 14, 2026

概括

与旧版本相比,一种新的信使RNA (mRNA) 构造物CJ-1显示出改善的蛋白质表达和较低的免疫反应. 这种优化的mRNA平台有望开发更安全,更有效的mRNA疗法.

科学领域:

生物技术是生物技术.
分子生物学分子生物学
免疫学免疫学免疫学

背景情况:

使者RNA (mRNA) 疗法在治疗各种疾病方面具有重大潜力.
一个关键的限制是从mRNA结构中实现持续和高效的蛋白质表达.
优化mRNA调节元件对于提高治疗疗效至关重要.

研究的目的:

开发和表征一种新的mRNA结构,CJ-1,具有改善的蛋白质表达和降低的免疫性.
与第一代mRNA相比,评估CJ-1的体外和体内性能.
评估CJ-1在蛋白质替代疗法中的治疗潜力.

主要方法:

系统优化关键的mRNA调节元素:5'和3'未翻译区域以及多 (A) 尾.
在各种细胞类型和体内小鼠模型中对CJ-1和第一代mRNA结构的蛋白质表达进行比较分析.
评估细胞因子反应以评估先天性免疫激活.
在脂质纳米颗粒中封装编码红色素 (EPO) 的CJ-1 mRNA,用于体内管理.

主要成果:

与第一代mRNA结构相比,CJ-1在多个实验系统中始终表现出优越的蛋白质表达.
CJ-1表现出明显较低的细胞因子反应,表明先天免疫激活减少.
在脂质纳米颗粒中内注射编码EPO的CJ-1mRNA导致持续的血清EPO水平.
在接受治疗的小鼠中观察到显著增加的网细胞计数和血红素,证明了治疗疗效.

结论:

CJ-1代表了一个有前途的,下一代mRNA平台,具有增强的蛋白质表达能力.
CJ-1构造表现出降低的免疫性,有助于改善mRNA治疗药物的安全性.
这些发现支持CJ-1的发展,以开发更有效,更安全的基于mRNA的疗法.

更多相关视频

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Published on: February 1, 2019

相关概念视频

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.